BCL2 and glioblastoma: The team developed an alternative approach for treating glioblastoma based upon the use of siRNA- or miRNA-carrying gene-regulatory SNAs to silence the expression of the atypical Bcl-2 family protein Bcl2-Like12 (Bcl2L12), a proline-rich protein characterized by a C-terminal 14 amino acid sequence with significant homology to the BH (Bcl-2 Homology) 2 domain found in several members of the Bcl-2 family [39,40,41,42].